Afshin Salsali

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Adriaan A. Voors, Christiane E. Angermann, John R. Teerlink et al. · Nature Medicine · 2022 · 895 citations · Full text

Medicine, Cardiology, Pharmacology +15

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise

Ele Ferrannini, Silvia Ramos, Afshin Salsali et al. · Diabetes Care · 2010 · 712 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

Ilkka Tikkanen, Kirsi Narko, Cordula Zeller et al. · Diabetes Care · 2014 · 462 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

Julio Rosenstock, Marisa L. Vico, Wei Li et al. · Diabetes Care · 2012 · 403 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

Julio Rosenstock, Ante Jelaska, Guillaume Frappin et al. · Diabetes Care · 2014 · 365 citations

Medicine, Pharmacology, Pharmacotherapy +17